Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:R07AX02
|
| gptkbp:brand |
gptkb:Kalydeco
|
| gptkbp:CASNumber |
873054-44-5
|
| gptkbp:chemicalFormula |
C24H28N2O3
|
| gptkbp:developedBy |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:genericName |
gptkb:ivacaftor
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kalydeco
|
| gptkbp:indication |
patients with specific CFTR mutations
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
CFTR potentiator
|
| gptkbp:otherName |
gptkb:VX-770
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
abdominal pain headache rash upper respiratory tract infection |
| gptkbp:usedFor |
cystic fibrosis
|
| gptkbp:bfsParent |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|